Hoth Therapeutics Amends Q3 2024 Financial Filing

Ticker: HOTH · Form: 8-K · Filed: 2024-12-02T00:00:00.000Z

Sentiment: neutral

Topics: amendment, financial-reporting, 10-Q

Related Tickers: HOTH

TL;DR

HOTH amended its Q3 2024 10-Q filing - check the financials.

AI Summary

On December 2, 2024, Hoth Therapeutics, Inc. filed an 8-K report detailing an amendment to its previously filed Form 10-Q for the quarterly period ended September 30, 2024. This amendment primarily concerns the financial statements and related disclosures within that 10-Q filing.

Why It Matters

This filing indicates a correction or update to Hoth Therapeutics' financial reporting for the third quarter of 2024, which could impact investor understanding of the company's financial position.

Risk Assessment

Risk Level: low — This is a routine amendment to a previous financial filing and does not appear to introduce new material risks.

Key Players & Entities

FAQ

What specific items were amended in the Form 10-Q for the period ended September 30, 2024?

The filing states that the amendment is to correct and update the financial statements and related disclosures previously filed in the Form 10-Q for the quarterly period ended September 30, 2024.

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report an amendment to Hoth Therapeutics, Inc.'s previously filed Form 10-Q for the quarterly period ended September 30, 2024.

When was the original Form 10-Q filed that is being amended?

The filing does not explicitly state the original filing date of the Form 10-Q being amended, only that the amendment is being reported on December 2, 2024.

What is Hoth Therapeutics, Inc.'s state of incorporation?

Hoth Therapeutics, Inc. is incorporated in Nevada.

What is the principal executive office address for Hoth Therapeutics, Inc.?

The principal executive offices are located at 590 Madison Ave, 21st Floor, New York, New York 10022.

From the Filing

0001213900-24-104567.txt : 20241202 0001213900-24-104567.hdr.sgml : 20241202 20241202161543 ACCESSION NUMBER: 0001213900-24-104567 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 47 CONFORMED PERIOD OF REPORT: 20241202 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20241202 DATE AS OF CHANGE: 20241202 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Hoth Therapeutics, Inc. CENTRAL INDEX KEY: 0001711786 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 821553794 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38803 FILM NUMBER: 241519227 BUSINESS ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 BUSINESS PHONE: (646)756-2997 MAIL ADDRESS: STREET 1: 590 MADISON AVENUE STREET 2: 21ST FLOOR CITY: NEW YORK STATE: NY ZIP: 10022 8-K 1 ea0223333-8k_hoth.htm CURRENT REPORT false 0001711786 0001711786 2024-12-02 2024-12-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM  8-K   CURRENT REPORT   Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934   Date of Report (Date of earliest event reported)  December 2, 2024   Hoth Therapeutics, Inc. (Exact name of registrant as specified in its charter)   Nevada   001-38803   82-1553794 (State or other jurisdiction of incorporation)   (Commission File Number)   (I. R. S. Employer Identification No.)   590 Madison Ave , 21 st Floor New York , New York 10022 (Address of principal executive offices, including ZIP code)   ( 646 ) 756-2997 (Registrant’s telephone number, including area code)   Not Applicable (Former name or former address, if changed since last report)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common stock, $0.0001 par value   HOTH   The Nasdaq Stock Market LLC   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).   Emerging growth company ☒   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐             Item 8.01 Other Events.   Hoth Therapeutics, Inc. (the “Company”) has prepared presentation materials (the “Presentation Materials”) that management intends to use from time to time on and after December 2, 2024, in presentations about the Company’s operations and performance. The Presentation Materials are filed as Exhibit 99.1 to this Current Report on Form 8-K.   The information contained in the Presentation Materials is summary information that should be considered within the context o

View on Read The Filing